Ionis Pharmaceuticals (NASDAQ: IONS) is one of 194 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its rivals? We will compare Ionis Pharmaceuticals to related businesses based on the strength of its risk, dividends, earnings, valuation, institutional ownership, analyst recommendations and profitability.

Risk and Volatility

Ionis Pharmaceuticals has a beta of 2.9, meaning that its stock price is 190% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals’ rivals have a beta of 1.54, meaning that their average stock price is 54% more volatile than the S&P 500.

Valuation & Earnings

This table compares Ionis Pharmaceuticals and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Ionis Pharmaceuticals $346.62 million -$86.55 million 372.56
Ionis Pharmaceuticals Competitors $220.75 million -$39.68 million -76.33

Ionis Pharmaceuticals has higher revenue, but lower earnings than its rivals. Ionis Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

89.0% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 48.7% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 2.1% of Ionis Pharmaceuticals shares are held by company insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Ionis Pharmaceuticals and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ionis Pharmaceuticals 2 6 6 0 2.29
Ionis Pharmaceuticals Competitors 500 2382 6496 122 2.66

Ionis Pharmaceuticals currently has a consensus target price of $50.38, indicating a potential downside of 9.83%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 18.06%. Given Ionis Pharmaceuticals’ rivals stronger consensus rating and higher probable upside, analysts clearly believe Ionis Pharmaceuticals has less favorable growth aspects than its rivals.


This table compares Ionis Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ionis Pharmaceuticals 3.46% 7.50% 1.58%
Ionis Pharmaceuticals Competitors -3,741.33% -114.15% -38.66%


Ionis Pharmaceuticals beats its rivals on 7 of the 13 factors compared.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company’s subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.

Receive News & Stock Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.